Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Antibody Appears Effective In Older COVID-19 Patients

Otilimab Targets Cytokine Prevalent In Elderly

Executive Summary

With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.

You may also be interested in...



Humanigen Raises Chances of Lenzilumab EUA With Severe COVID-19 Data

Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.

Coronavirus Update: Takeda Contractor To Manufacture J&J Vaccine; Moderna Starts Pediatric Trial

Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.

Coronavirus Update: At One-Year Mark, WHO Stresses Importance Of Fair Vaccine Distribution

Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;